Trial Profile

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
21 May 2026 According to a Genmab media release, According to a Genmab media release, data from this study will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
03 Sep 2025 According to an AbbVie media release, 88 patients received the first full 48 mg dose of epcoritamab monotherapy in the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com